Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 1Phase 2 Interventional

A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients

NCT00299338
View directory record Official record
Conditions
HIV Infections
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2006 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

NCT00408538
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 microbicide gel (0.1% and 0.25%), placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Contrast Enhanced Ultrasound in COVID-19

NCT04640038
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions
Sulfur hexafluoride lipid-type A microspheres
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Minute to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Minority AIDS Initiative Retention and Re-Engagement Project

NCT01616940
View directory record Official record
Conditions
HIV/AIDS
Interventions
Enhanced Peer Intervention
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 31, 2026, 3:27 AM EDT
Active, not recruiting Not applicable Interventional

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

NCT06391489
View directory record Official record
Conditions
Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
Interventions
HOBSCOTCH-PACS
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (2004-2005 Formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Months to 9 Months
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
8
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 31, 2026, 3:27 AM EDT
Terminated Not applicable Interventional Results available

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04382391
View directory record Official record
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Targeting Effective Analgesia in Clinics for HIV - Intervention

NCT02564341
View directory record Official record
Conditions
HIV Infection, Pain, Drug Dependence
Interventions
Collaboration with an IT enabled nurse care manager, Education and academic detailing, Facilitated access to a specialist in addictions
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIV Prevention Among Vulnerable Male Youth

NCT01771237
View directory record Official record
Conditions
Homosexuality, Male, HIV, Substance-related Disorders, Sexual Dysfunctions, Psychological
Interventions
MyPeeps Manualized Group Intervention, Standard Sexual Health Education
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
16 Years to 20 Years · Male only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety of Dapivirine Gel and Film Formulations

NCT01548560
View directory record Official record
Conditions
HIV Infections
Interventions
Dapivirine Vaginal Film, Dapivirine Vaginal Gel
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 vaccine, Control
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
3,855 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
15
States / cities
Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

NCT01228318
View directory record Official record
Conditions
HIV Infection, Bone Loss, Osteopenia, Osteoporosis
Interventions
Zoledronic acid
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 31, 2026, 3:27 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 31, 2026, 3:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities

NCT05449418
View directory record Official record
Conditions
COVID-19
Interventions
Full Intervention, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Expansion to Interdisciplinary HIV Prevention in Women

NCT01994603
View directory record Official record
Conditions
HIV, AIDS, Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder
Interventions
Opt-in or Opt-out testing, Focus Group
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Text Message Study

NCT05533918
View directory record Official record
Conditions
COVID-19
Interventions
Text-Messaging (TM), Patient Navigation (PN)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
31,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 31, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

NCT03301090
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Placebo, REGN3048, REGN3051
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 31, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597
View directory record Official record
Conditions
Covid19
Interventions
BGE-175, Placebo
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
50 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Mesa, Arizona • Chula Vista, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 3:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

NCT04240210
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Symtuza
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 3:27 AM EDT